Daniel J. Ford

Atropisomeric small molecule Bcl-2 ligands: determination of bioactive conformation.

Rachel A. Garlish, C. Stubberfield, G. Trevitt, 2009, Bioorganic & medicinal chemistry letters.

Identification of differential protein binding affinities in an atropisomeric pharmaceutical compound by noncovalent mass spectrometry, equilibrium dialysis, and nuclear magnetic resonance.

Hannah J. Maple, Rachel A. Garlish, Richard J. Taylor, 2013, Analytical chemistry.

Discovery of Potent Cyclic Sulfopeptide Chemokine Inhibitors via Reprogrammed Genetic Code mRNA Display.

R. Payne, M. Stone, S. Foster, 2020, Journal of the American Chemical Society.

Tetrahydroisoquinoline amide substituted phenyl pyrazoles as selective Bcl-2 inhibitors.

C. Stubberfield, Brian Hutchinson, G. Trevitt, 2009, Bioorganic & medicinal chemistry letters.

Synthetic Sansanmycin Analogues as Potent Mycobacterium tuberculosis Translocase I Inhibitors.

Roger G. Linington, E. Rubin, R. Payne, 2021, Journal of medicinal chemistry.

Discovery of a Potent, Orally Bioavailable PI4KIIIβ Inhibitor (UCB9608) Able To Significantly Prolong Allogeneic Organ Engraftment in Vivo.

S. Steinbacher, T. Ceska, W. Pitt, 2018, Journal of medicinal chemistry.

Crystal Structure of Chimaeric Bcl2-xL and Phenyl Tetrahydroisoquinoline Amide Complex

M. Lamers, C. Stubberfield, G. Trevitt, 2008 .

Late-stage modification of peptides and proteins at cysteine with diaryliodonium salts

J. Mackay, R. Payne, M. Larance, 2021, Chemical science.

Potent Cyclic Peptide Inhibitors of FXIIa Discovered by mRNA Display with Genetic Code Reprogramming.

C. Jackson, R. Payne, H. Suga, 2021, Journal of medicinal chemistry.